Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Ups Its Stake In Theravance
by Ann M. Thayer
April 9, 2012
| A version of this story appeared in
Volume 90, Issue 15
GlaxoSmithKline has paid $213 million to increase its stake in South San Francisco-based Theravance by 8.5% to a total of 26.8%. GSK has been a partner of the small-molecule drug discovery firm since 2002. They have collaborated on the development of Relovair, which combines a long-acting β2 agonist with an inhaled corticosteroid to treat respiratory diseases. GSK will soon file for approval of the drug in the U.S. and Europe. The companies are working on another respiratory disease drug that is in Phase II development.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter